Critical Care Medicine Research

Hypertonic Saline Study

  • Principal Investigator:
    • Lakshmi Raman, MD
  • For more information, contact:
    • Anne Marie Jones, MS CRC (214) 456-8436
  • A randomized trial of the safety and effectiveness of 3% versus 23% hypertonic saline for the treatment of pediatric intracranial hypertension
  • Patients who experience intracranial hypertension following a severe traumatic brain injury will be randomized to receive either 3% hypertonic saline or 23% hypertonic saline. Intracranial pressure will be closely monitored throughout treatment
  • The goal is to determine the effect of 23% hypertonic saline on intracranial hypertension in relation to 3% hypertonic saline, with the hypothesis that 23% hypertonic saline will be more efficacious in reducing intracranial hypertension
  • Enrollment Criteria
    • Children ages 3 months to <18 years old
    • Acute TBI
    • GCS 3-8
    • Glasgow Motor Score <6
    • ICP monitor (or imminent plan to place an ICP monitor) 

Therapeutic Hypothermia After Cardiac Arrest (THAPCA)

  • Principal Investigator:
    • Joshua Koch, MD
  • For more information contact:
    • Evin Shirley, BS (214) 456-9501
  • Participants are enrolled in one of two randomized, controlled clinical trials. One evaluates participants who suffered cardiac arrest outside of the hospital setting, while the other evaluates participants who suffered cardiac arrest within the hospital setting
  • Within each trial, there are two active treatment groups: therapeutic hypothermia (cooling the patient to 89.6-93.2 Fahrenheit) and therapeutic normothermia (maintaining the patient at 96.8-99.5 Fahrenheit)
  • Both trials are trying to control body temperature and preclude fever, which commonly occurs after cardiac arrest and can lead to more severe outcomes
  • Treatment is managed for 5 days; during treatment, participants lie on a mattresses and are covered with thermo regulator blankets.  Machines circulate water through the blankets to control the participants’ body temperatures
  • The therapeutic hypothermia group in each trial receives the hypothermia treatment for two days and then normothermia treatment for three days, while the patients in the therapeutic normothermia groups receive normothermia treatment for all five days
  • Neurological and neuropsychological outcomes are measured on all patients at approximately  12 months following the cardiac arrest event